Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLobe Sciences Ltd

Lobe Sciences Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.04 CAD 0.00(0%)
Last update at 2026-11-04T20:02:00Z
VOLUME
56861
Market Cap
28.30M

Momentum Score

…

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.02
Low
0.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Lobe Sciences Ltd (LOBE.CN) are limited and company filings and investor materials provide minimal detail on its operations or product portfolio. Based on the company name and scarce available information, it may be involved in biotechnology or health-related products where long-term growth drivers would typically include clinical progress, regulatory approvals and commercial adoption, which could support investor interest if clear milestones are reported.

The most important investment risks are the lack of transparent public information, typical early-stage operational and clinical development risk, financing and dilution risk, and regulatory uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.04
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.25M
Debt / Equity
-
ROE
-3651.86%
Net Debt
1.51M
ROCE
-80.88%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -4.86M -4.39M -4.50M -12.25M -23.84M
Minority interest 0.43M 0.00M - - -
Net income -4.43M -4.42M -4.71M -12.25M -9.66M
Selling general administrative 3.54M 1.78M 2.88M 3.69M 4.94M
Gross profit 0.00M 0.13M 0.82M 0.00M -
Reconciled depreciation 0.00M 0.08M 0.04M 0.01M 0.00M
Ebit - - - -4.12M -6.32M
Ebitda - - - -4.11M -
Operating income -4.18M -2.12M -3.36M -4.12M -6.32M
Interest expense 0.60M 0.19M 0.04M 0.00M 0.00M
Tax provision 0.00M 0.03M 0.20M 0.00M -1.02M
Interest income 0.02M 0.00M - - -
Net interest income -0.58M -0.19M -0.04M 0.00M -
Income tax expense - - - - -1.02M
Total revenue 0.00M 0.14M 0.84M 0.00M 0.00M
Total operating expenses 4.18M 2.25M 4.20M 4.12M 6.32M
Cost of revenue 0.00M 0.00M 0.02M 0.00M -
Total other income expense net -0.11M -2.08M -1.10M -8.13M -17.53M
Discontinued operations - - - - 13.16M
Net income from continuing ops -4.86M -4.42M -4.71M -12.25M -22.82M
Net income applicable to common shares - - - -12.25M -9.66M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 7.59M 0.26M 2.30M 1.75M 12.10M
Other current assets - - - - 0.20M
Total liab 2.70M 3.37M 2.46M 1.30M 0.80M
Total stockholder equity 2.36M -3.11M -0.16M 0.45M 11.29M
Other current liab 0.21M 0.60M - - -
Common stock - - - 25.22M 24.84M
Capital stock 34.71M 30.61M 27.62M 25.22M 24.84M
Retained earnings -39.25M -40.10M -35.68M -30.98M -18.47M
Other assets - - - - 0.07M
Cash 5.85M 0.24M 0.14M 0.91M 1.14M
Total current liabilities 2.43M 2.27M 2.46M 1.30M 0.80M
Net debt - 1.51M 0.19M - -
Short long term debt - 0.64M 0.33M - -
Other stockholder equity - - - 4.90M 3.68M
Total current assets 7.59M 0.26M 0.32M 1.04M 9.67M
Long term investments - - 0.00M 0.68M 0.96M
Net tangible assets - - - 0.42M 11.25M
Short term investments 1.69M - - 0.00M 6.28M
Net receivables 0.05M 0.01M 0.01M 0.02M 1.76M
Long term debt 0.27M 1.11M - - -
Inventory - 0.00M 0.02M 0.00M -
Accounts payable 1.98M 0.78M 1.92M 1.20M 0.75M
Non currrent assets other - - - - 1.36M
Non current assets total 0.00M 0.00M 1.98M 0.71M 2.43M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Investments -1.69M 0.00M 0.00M 1.74M -0.45M
Change to liabilities - - - 0.50M 0.24M
Total cashflows from investing activities - - - - 1.07M
Net borrowings 0.17M 0.56M 0.34M 0.00M -0.09M
Total cash from financing activities 8.76M 0.56M 0.95M 2.50M 4.92M
Change to operating activities - - - 0.17M 0.09M
Net income -4.43M -4.42M -4.71M -12.25M -9.66M
Change in cash 5.62M 0.10M -0.77M -0.23M 0.97M
Begin period cash flow 0.24M 0.14M 0.91M 1.14M 0.17M
End period cash flow 5.85M 0.24M 0.14M 0.91M 1.14M
Total cash from operating activities -1.42M -0.46M -1.72M -2.73M -5.04M
Issuance of capital stock 0.35M 0.00M 0.68M 0.00M 5.17M
Depreciation 0.00M 0.08M 0.04M 0.01M 0.01M
Change to inventory 0.00M 0.00M 0.02M 0.00M -
Change to account receivables - - - 0.18M -0.14M
Other cashflows from financing activities - - - -0.04M -0.20M
Change to netincome - - - 8.66M 4.44M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 2.16M 1.33M 1.52M 0.85M 0.19M
Stock based compensation 0.53M 0.27M 0.30M 0.62M 0.92M
Other non cash items 0.60M 0.19M 1.10M 7.04M 11.15M
Free cash flow -1.42M -0.46M -1.72M -2.73M -5.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LOBE
Lobe Sciences Ltd		 -
-%		 0.04 - - 2.44 15.58 5.75 1.64
DRUG
Bright Minds Biosciences Inc		 -10.97
29.58%		 26.11 - - - 13.50 - -0.10
METX
ME Therapeutics Holdings Inc.		 -0.05
4.55%		 1.05 - - - 72.00 - -
TELI
Telescope Innovations Corp.		 0.01
1.56%		 0.33 - - 4.32 6.45 4.32 -1.62
DTC
Defence Therapeutics Inc		 -0.01
1.47%		 0.34 - - - 89.80 - -9.99

Profile*

Lobe Sciences Ltd

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.

1771 Robson Street, Vancouver, BC, Canada, V6G 3B7

949-505-5623

https://www.lobesciences.com

Name Title Year Born
Dr. Frederick Dominick Sancilio M.S., Ph.D. Chairman & CEO 1950
Mr. Charles F. Goulburn M.B.A. President 1962
Mr. Yong Yao EVP & Chief Financial Officer 1968
Mr. Maghsoud Dariani B.S., M.S. Chief Science Officer 1954
Dr. Herman Williams M.B.A., M.D., M.P.H. CEO Alt, Inc 1960
Mr. Mirza Rahimani Chief Financial Officer 1980
Dr. Robert Miller Ph.D. Senior Vice President of Quality and Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…